RAB21 was previously reported to be associated with remission (p = 0.0103) in a GWAS of selective serotonin reuptake inhibitors in MDD patients43 and AQR as related to neuroticism (p = 9.58 × 10−8) and worry (p = 2.06 × 10−6)44, a well-known symptom in depression. Here, RAB21 is linked to depressive symptom measurement.